What does tesamorelin actually do in the body?

Last updated 2026-07-24

What is tesamorelin, in plain terms?

Tesamorelin is a 44-amino acid peptide, a synthetic analogue of growth hormone-releasing hormone (GHRH). It's not growth hormone itself. It's a signal that tells your pituitary gland to make and release more of its own GH, which then raises IGF-1 levels in the liver and elsewhere ^[1]. The FDA approved it under the brand name Egrifta (and later Egrifta SV, a reformulated version) for one specific job: reducing excess visceral abdominal fat in HIV patients with lipodystrophy ^[1]. That's it. That's the approved use. Everything else you hear about tesamorelin (general fat loss, anti-aging, athletic recovery) is off-label extrapolation from a drug that was built, tested, and approved for a narrow metabolic problem. A 2011 review in Nature Reviews Drug Discovery describes tesamorelin as a GHRH analogue developed specifically to address the visceral fat accumulation seen in HIV-associated lipodystrophy, a condition where antiretroviral therapy and the disease itself reshape body fat distribution ^[1]. Understanding that origin story matters, because it explains why the drug does what it does and why the evidence base is deep in one narrow lane and thin everywhere else. If you want the full mechanism-to-outcome picture, the tesamorelin hub page walks through the GHRH pathway and receptor biology in more depth.

How does tesamorelin work mechanically (the GHRH pathway)?

Tesamorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary. That binding triggers a pulse of growth hormone release, mimicking (roughly) the body's natural GHRH signaling rhythm rather than just flooding the system with GH directly. The GH pulse then travels to the liver, where it drives IGF-1 production. IGF-1 is the downstream messenger that does a lot of the actual metabolic work: lipolysis in visceral fat depots, effects on hepatic fat handling, and broader tissue signaling. This two-step chain (GHRH analogue to GH pulse to IGF-1 rise) is the core mechanism, and it's why tesamorelin behaves differently than injecting synthetic HGH directly. It works through the pituitary's own machinery rather than bypassing it ^[1]. A 2015 population pharmacokinetic analysis in HIV-infected patients and healthy subjects mapped out how tesamorelin is absorbed and cleared after subcutaneous injection, providing the dosing and exposure data that underpins the approved regimen ^[2]. This kind of pharmacokinetic modeling is part of why the approved 2 mg daily subcutaneous dose looks the way it does. It's not an arbitrary number, it's derived from exposure-response modeling across patient populations. One finding worth flagging: a 2011 study on inflammatory markers found that tesamorelin's reduction in visceral fat correlated with changes in certain inflammatory markers, suggesting the drug's effects go beyond simple fat volume and touch adipose tissue biology more broadly ^[3].

What did the phase 3 trials actually show?

The core evidence for tesamorelin comes from two large multicenter, double-blind, placebo-controlled phase 3 trials in HIV patients with excess abdominal fat, later pooled and analyzed together with safety extension data. That pooled analysis, published in the Journal of Clinical Endocrinology and Metabolism in 2010, is the single most cited piece of evidence for the drug's approval ^[4]. The pooled trials showed statistically significant reductions in visceral adipose tissue (VAT) with tesamorelin versus placebo over 26 weeks of treatment, alongside improvements in triglycerides and other metabolic markers, with an acceptable safety profile in the extension phase ^[4]. A 2026 meta-analysis of randomized controlled trials pooling tesamorelin's body composition, hepatic fat, and metabolic outcomes in HIV-associated lipodystrophy reinforces this: consistent VAT reduction across trials, plus signals for improved hepatic fat and metabolic markers ^[5]. Here's a rough summary of what the trial evidence base covers: | Outcome measured | Direction of effect | Source |

How much visceral fat does tesamorelin actually reduce?

Across the phase 3 program and subsequent trials, tesamorelin produced measurable VAT reductions over 26-52 weeks of treatment, generally in the range clinicians describe as clinically meaningful for this population, though exact percentage reductions vary by trial and measurement method (CT-based VAT area is the standard metric) ^{[4] [5]}. A 2019 randomized double-blind trial specifically looking at NAFLD in HIV found that tesamorelin reduced hepatic fat fraction measured by MRI-PDFF, with the effect linked to the drug's action on visceral fat and liver fat handling together, more than abdominal girth ^[7]. That's an important distinction: the drug isn't just shrinking waistlines, it's affecting fat stored around organs and in the liver, which is metabolically the more dangerous fat depot. A 2017 study found that visceral fat reduction with tesamorelin was associated with improved liver enzyme levels in HIV patients, tying the anatomical change (less VAT) to a functional lab marker (better ALT/AST) ^[6]. That kind of linked finding, where a marker of fat mass connects to a marker of organ function moving in the right direction, is one of the more convincing threads in the tesamorelin evidence base. For readers weighing whether the visceral fat effect is dose-dependent or timeline-dependent, the tesamorelin dosage page breaks down how the approved regimen was built from the pharmacokinetic and phase 3 data.

Does tesamorelin work on liver fat (NAFLD) too?

Yes, and this is one of the more interesting secondary findings in the tesamorelin literature. The 2019 Lancet HIV trial was designed specifically to test tesamorelin against NAFLD in HIV patients and found a real reduction in hepatic fat fraction on MRI over the study period, in a randomized, double-blind, multicenter design ^[7]. A 2020 study in JCI Insight went further, mapping hepatic transcriptomic signatures in HIV-associated NAFLD after tesamorelin treatment, essentially looking at which genes turn on or off in liver tissue in response to the drug ^[10]. A related 2021 study in Scientific Reports used targeted proteomic and transcriptomic approaches to delineate the specific response pathways tesamorelin triggers in NAFLD, moving the mechanism story from "fat goes down" to "here's what's happening at the molecular level in liver cells" ^[11]. None of this makes tesamorelin an approved NAFLD drug. It isn't. These are mechanistic and secondary-outcome studies within the HIV lipodystrophy population, not a separate approval pathway. But they do help explain why liver fat and visceral fat move together under this drug: the GHRH-to-GH-to-IGF-1 axis touches both.

Is tesamorelin only approved for HIV-related fat, or does it work for general fat loss?

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy with excess abdominal fat, under the brand names Egrifta and Egrifta SV ^[1]. There is no FDA approval for general fat loss, body recomposition in people without HIV, athletic performance, or anti-aging use. That matters practically because the strength of the evidence (real phase 3 trials, pooled safety data, a defined dosing regimen) applies specifically to that population and that condition. Extrapolating the visceral fat results to a healthy 45-year-old wanting a flatter stomach is a leap the trial data doesn't support. Nobody has run tesamorelin through the same phase 3 rigor in a general population seeking cosmetic fat loss, and it's worth being honest that this gap exists rather than pretending the HIV data transfers cleanly. A 2022 review on the approach to patients with lipodystrophy in the Journal of Clinical Endocrinology and Metabolism frames lipodystrophy as a distinct clinical syndrome requiring specific diagnostic criteria, not simply "having visceral fat" ^[12]. A 2012 paper on diagnosing lipodystrophy syndromes reinforces that this is a defined medical condition with its own workup, not a spectrum that includes ordinary overweight or aging-related fat gain ^[13]. Where tesamorelin gets used off-label for broader fat loss or GH support in aesthetic and longevity medicine, that use sits outside the approved label and outside the trial evidence base described above. A 2026 review in the International Journal of Molecular Sciences on therapeutic peptides in aesthetic, metabolic, and endocrine conditions discusses tesamorelin alongside other GH-axis peptides in this broader off-label context, which is useful for understanding the landscape but shouldn't be read as equivalent evidence to the phase 3 HIV trials ^[14].

What does tesamorelin do to IGF-1 and growth hormone levels?

Tesamorelin's whole mechanism runs through raising GH pulses and, downstream, IGF-1 levels. That's the pharmacodynamic signature clinicians actually monitor. In practice, IGF-1 is the lab value used to track whether the drug is doing what it's supposed to do, since GH itself pulses too much to measure reliably with a single blood draw. A 2013 review on growth hormone in the aging male in Best Practice & Research Clinical Endocrinology & Metabolism discusses the broader physiology of the GH/IGF-1 axis and how it changes with age, providing useful background on why GHRH analogues like tesamorelin are of interest beyond the HIV indication (though again, that interest hasn't translated into a separate approval) ^[15]. A 2024 study on tesamorelin's efficacy and safety in people with HIV on integrase inhibitors looked specifically at whether newer antiretroviral regimens change how tesamorelin performs, since drug-drug interactions and metabolic baseline differences matter for a population whose treatment landscape keeps shifting ^[16]. This is a good example of how the tesamorelin evidence base keeps getting refreshed for its actual approved population, even as off-label interest in other populations grows separately.

What are the trial-documented side effects and safety signals?

The phase 3 pooled analysis and its safety extension data describe an acceptable safety profile over extended use, with the kinds of side effects you'd expect from a drug that raises GH and IGF-1: injection site reactions, joint or muscle discomfort (arthralgia/myalgia), and effects on glucose metabolism that need monitoring ^[4]. A 2012 Annals of Pharmacotherapy review of tesamorelin as a GHRH analogue for HIV-associated lipodystrophy discusses these effects in the context of clinical use and dosing considerations ^[17]. A separate 2011 review in Drugs covering tesamorelin's use in HIV lipodystrophy management similarly frames the safety profile within its approved indication ^[18]. Raising GH and IGF-1 is not a metabolically neutral act. It can affect insulin sensitivity and glucose handling, which is exactly why the drug is monitored closely in trials and why it's not something to self-manage without lab follow-up. For the fuller side effect rundown, including what's mild and what warrants stopping treatment, see tesamorelin peptide side effects. On the manufacturing and sourcing side, it's worth knowing that tesamorelin's regulatory status differs from many other peptides circulating in the wellness space. It's an FDA-approved drug with an NDA on file (searchable via Drugs@FDA) ^[19], not a compounded or research-use substance governed by the 503A/503B bulk drug substance lists ^{[20] [21]}.

How is tesamorelin actually dosed in trials and in practice?

The FDA-approved dosing for Egrifta is 2 mg administered once daily by subcutaneous injection, typically in the abdomen, based on the pharmacokinetic and phase 3 exposure data described above ^{[2] [4]}. Egrifta SV, the reformulated version, uses a different reconstitution and delivery setup but targets the same daily dosing principle. A 2023 post hoc analysis of the phase 3 double-blind placebo-controlled trial looked specifically at whether tesamorelin's effects differ in people with versus without dorsocervical fat (the fat pad sometimes called a "buffalo hump" in HIV lipodystrophy), finding that treatment effects on VAT held across both subgroups, though presence of dorsocervical fat is a distinct clinical feature worth separate attention ^[22]. That's a useful reminder that lipodystrophy isn't one uniform fat pattern, it shows up differently across patients, and trial data helps clarify which effects generalize within the approved population and which don't. For the mechanics of drawing up and administering the approved dose, including reconstitution steps, see tesamorelin reconstitution and the tesamorelin dosage calculator. Cost is a real factor too. Egrifta as a branded pharmaceutical carries a meaningfully higher price than many peptides sold outside the approved-drug channel; the tesamorelin cost page breaks down what drives that price difference and what a provider-reviewed, pharmacy-fulfilled option actually looks like for people pursuing this through Tesamorelin Co's provider-reviewed route.

How does tesamorelin compare to other GH-axis peptides people talk about?

Tesamorelin sits in a specific category: GHRH analogues that stimulate the pituitary's own GH release, as opposed to GH secretagogues (like ipamorelin or MK-677) that work through a different receptor (the ghrelin/GHS-R pathway), or synthetic HGH itself, which bypasses the pituitary entirely. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews on therapeutic peptides in orthopaedics discusses GH-axis peptides including GHRH analogues in the context of musculoskeletal applications, noting both interest and evidence gaps in this space ^[23]. A companion 2026 primer in the American Journal of Sports Medicine aimed at orthopaedic and sports medicine physicians covers injectable peptide therapy broadly, giving clinicians a framework for thinking about where the evidence is solid (tesamorelin's HIV indication) versus where it's thin (most other GH-axis peptide use in athletes) ^[24]. A 2026 Sports Medicine review on the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance draws a similar line: approved peptides with real trial data exist, but they're a small subset of what's marketed, and tesamorelin's FDA approval puts it in a different evidence tier than most peptides discussed for performance or recovery use ^[25]. If you're comparing tesamorelin against other options in this space, the site's comparisons hub is the place to look at that side by side. One more regulatory note: tesamorelin's synthetic peptide structure means anti-doping labs have had to develop specific detection methods for GHRH analogues, since these compounds can be misused to boost endogenous GH in sport. A 2021 paper in Drug Testing and Analysis covers advances in detecting synthetic GHRH analogues, which is a good marker of how seriously this class of compound is treated in regulated sport ^[26].

What does tesamorelin NOT do (the honest limits)?

Tesamorelin does not directly replace growth hormone the way injectable HGH does. It stimulates your own pituitary to make more, which means someone with significantly impaired pituitary function may not respond the same way as someone with normal GHRH receptor signaling. It is not an approved weight loss drug, not an approved muscle-building drug, and not an approved anti-aging therapy. The phase 3 evidence is specific to visceral fat reduction and related metabolic markers in HIV-associated lipodystrophy ^{[4] [5]}. Extending claims beyond that indication outpaces what the trials measured. It's also not a fast fix. Trial timelines run in the 26 to 52 week range to show measurable VAT changes, not days or a couple of weeks ^[4]. Anyone expecting a quick before-and-after is working from a different drug's marketing, not tesamorelin's actual trial data. And it's not risk-free. Raising GH and IGF-1 pharmacologically requires monitoring, particularly around glucose metabolism, and the approved label reflects a risk-benefit calculation made specifically for HIV lipodystrophy patients with a defined medical need, not a general wellness population ^{[17] [18]}.

Frequently asked questions

What does tesamorelin actually do to the body?

Tesamorelin is a GHRH analogue that stimulates the pituitary to release more growth hormone, which raises IGF-1 and reduces visceral abdominal fat. In FDA-approved use, it's specifically for HIV-associated lipodystrophy, where phase 3 trials showed measurable visceral fat reduction plus improvements in liver enzymes and some metabolic markers over 26 to 52 weeks of treatment.

Is tesamorelin FDA-approved, and for what?

Yes. Tesamorelin is FDA-approved under the brand names Egrifta and Egrifta SV specifically for reducing excess visceral abdominal fat in HIV patients with lipodystrophy. It is not approved for general fat loss, muscle building, athletic performance, or anti-aging use; those are off-label applications outside the approved indication.

How long does it take for tesamorelin to reduce visceral fat?

Phase 3 trials measured visceral adipose tissue changes over 26 weeks, with safety extension data extending further, showing statistically significant reductions versus placebo in that window. This isn't a fast-acting drug; meaningful CT-measured VAT changes take months, not days or weeks, based on the pooled phase 3 trial data.

Does tesamorelin help with liver fat or NAFLD?

A 2019 randomized, double-blind trial found tesamorelin reduced hepatic fat fraction (measured by MRI) in HIV patients with NAFLD, and a separate 2017 study linked visceral fat reduction to improved liver enzymes. These are real findings within the HIV population studied; tesamorelin is not separately FDA-approved as a NAFLD treatment.

Can tesamorelin be used for general fat loss without HIV?

That would be off-label use. The FDA approval and the phase 3 trial evidence are specific to HIV-associated lipodystrophy. Nobody has run tesamorelin through equivalent phase 3 trials in a general, non-HIV population seeking cosmetic fat loss, so the strong evidence base doesn't transfer cleanly to that use case.

How does tesamorelin work differently from injectable HGH?

Tesamorelin is a GHRH analogue: it binds pituitary receptors and stimulates your own gland to release GH in a pulsatile pattern. Injectable HGH bypasses the pituitary and delivers growth hormone directly. This mechanistic difference is part of why tesamorelin's side effect and monitoring profile differs from direct HGH replacement.

What is the approved dose of tesamorelin?

The FDA-approved dose for Egrifta is 2 mg once daily by subcutaneous injection, a regimen built from population pharmacokinetic modeling in HIV-infected patients and healthy subjects. Egrifta SV uses a reformulated delivery system targeting the same daily dosing principle. Dosing outside this framework hasn't been validated by the same trial data.

What side effects showed up in tesamorelin's clinical trials?

Pooled phase 3 data and safety extension studies documented injection site reactions, joint and muscle discomfort, and effects on glucose metabolism requiring monitoring. The overall profile was described as acceptable within the studied HIV lipodystrophy population, but raising GH and IGF-1 pharmacologically is not without metabolic tradeoffs that need lab follow-up.

Does tesamorelin affect inflammation markers?

A 2011 study found that tesamorelin's visceral fat reduction correlated with changes in inflammatory markers in HIV patients with excess abdominal fat, suggesting effects beyond simple fat volume. This is a secondary finding within the approved indication, not evidence for a separate anti-inflammatory use.

Is tesamorelin the same as growth hormone releasing hormone (GHRH)?

It's a synthetic analogue of GHRH, not identical to the natural hormone, engineered for stability and a defined dosing profile. It works through the same receptor pathway as natural GHRH, stimulating pituitary GH release, which is why its downstream effects (raised IGF-1, reduced visceral fat) mirror what you'd expect from boosting the natural GHRH signal.

Does tesamorelin help with cognitive function in HIV patients?

A 2025 study in the Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity as a specific research question. This is an active area of study within the approved population rather than an established, labeled benefit, so treat it as an emerging finding, not a confirmed indication.

How is tesamorelin regulated compared to compounded peptides?

Tesamorelin (as Egrifta/Egrifta SV) is an FDA-approved drug with an approved New Drug Application, searchable on Drugs@FDA. That's a different regulatory status than compounded peptides governed by the 503A and 503B bulk drug substance lists under 21 CFR 216.23 and 216.24, which apply to substances without full FDA drug approval.

Sources

1. PubMed, Nature Reviews Drug Discovery, 2011: Tesamorelin is a GHRH analogue developed for HIV-associated lipodystrophy, working through the GHRH receptor to raise GH and IGF-1.
2. PubMed, Clinical Pharmacokinetics, 2015: Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects underpins the approved dosing regimen.
3. PubMed, AIDS, 2011: Tesamorelin's visceral fat reduction correlated with changes in inflammatory markers in HIV patients with excess abdominal fat.
4. PubMed, Journal of Clinical Endocrinology and Metabolism, 2010: Pooled phase 3 double-blind placebo-controlled trials with safety extension data showed significant visceral fat reduction and metabolic improvements with tesamorelin.
5. PubMed, Obesity Research & Clinical Practice, 2026: Meta-analysis of randomized controlled trials confirms consistent visceral fat and hepatic fat improvements from tesamorelin across studies.
6. PubMed, AIDS, 2017: Visceral fat reduction with tesamorelin was associated with improved liver enzyme levels in HIV patients.
7. PubMed, The Lancet HIV, 2019: Randomized double-blind trial found tesamorelin reduced hepatic fat fraction in HIV patients with non-alcoholic fatty liver disease.
8. PubMed, AIDS, 2021: Tesamorelin improved fat quality independent of changes in overall fat quantity.
9. PubMed, Journal of Infectious Diseases, 2025: Study examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity.
10. PubMed, JCI Insight, 2020: Tesamorelin affects hepatic transcriptomic signatures in HIV-associated NAFLD.
11. PubMed, Scientific Reports, 2021: Targeted proteomic and transcriptomic analysis delineated tesamorelin's response pathways in HIV-associated NAFLD.
12. PubMed, Journal of Clinical Endocrinology and Metabolism, 2022: Lipodystrophy is a distinct clinical syndrome with defined diagnostic criteria, not a general fat-gain spectrum.
13. PubMed, Annales d'Endocrinologie, 2012: Diagnosing a lipodystrophy syndrome requires specific clinical criteria distinct from ordinary overweight.
14. PubMed, International Journal of Molecular Sciences, 2026: Review discusses tesamorelin among GH-axis peptides used off-label in aesthetic, metabolic, and endocrine contexts.
15. PubMed, Best Practice & Research Clinical Endocrinology & Metabolism, 2013: Review of growth hormone physiology in aging males provides background on the GH/IGF-1 axis relevant to GHRH analogues.
16. PubMed, AIDS, 2024: Study evaluated tesamorelin's efficacy and safety in people with HIV on integrase inhibitor regimens.
17. PubMed, The Annals of Pharmacotherapy, 2012: Review discusses tesamorelin's side effect profile and clinical use as a GHRH analogue for HIV-associated lipodystrophy.
18. PubMed, Drugs, 2011: Review of tesamorelin's use in managing HIV-associated lipodystrophy covers its approved-indication safety profile.
19. FDA, Drugs@FDA database: Tesamorelin (Egrifta/Egrifta SV) is searchable as an FDA-approved drug product with an approved New Drug Application.
20. eCFR, 21 CFR 216.23: The 503A bulk drug substances list governs compounding status distinct from full FDA drug approval.
21. eCFR, 21 CFR 216.24: The 503B bulk drug substances list governs outsourcing facility compounding status distinct from full FDA drug approval.
22. PubMed, Journal of Clinical and Translational Science, 2023: Post hoc phase 3 analysis found tesamorelin's visceral fat effect held across patients with and without dorsocervical fat.
23. PubMed, Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026: Review discusses therapeutic peptides including GH-axis peptides in orthopaedic applications and notes evidence gaps.
24. PubMed, American Journal of Sports Medicine, 2026: Primer for sports medicine physicians on injectable peptide therapy discusses evidence tiers among GH-axis peptides.
25. PubMed, Sports Medicine, 2026: Review distinguishes approved peptides with trial-backed evidence from unapproved peptides marketed for athletic performance.
26. PubMed, Drug Testing and Analysis, 2021: Anti-doping science has developed specific detection methods for synthetic GHRH analogues due to misuse potential in sport.